Oliveira Ana M, Faller Kiterie, Madden Megan
J Am Vet Med Assoc. 2025 May 21;263(9):1-6. doi: 10.2460/javma.25.02.0119. Print 2025 Sep 1.
To evaluate whether gastrointestinal signs are more frequently observed in dogs with steroid-responsive meningitis-arteritis (SRMA) compared to a control population. We hypothesized that dogs with SRMA would have higher odds of exhibiting gastrointestinal signs than controls.
In a single-center, retrospective case-control study, dogs diagnosed with SRMA between December 2018 and December 2023 were identified through the institutional database medical records of the Hospital for Small Animals, Royal (Dick) School of Veterinary Studies, University of Edinburgh. Data collected included signalment, cerebrospinal fluid analysis results, serum C-reactive protein levels, presenting clinical signs, and the presence of gastrointestinal signs before and during the initial phase of corticosteroid treatment. The control group consisted of age-matched dogs hospitalized during the same time period and for a similar duration that had not been referred for gastrointestinal signs and had full medical records available.
50 dogs were included in each group. Gastrointestinal signs were more frequently reported in the SRMA group, with significantly increased odds of vomiting (adjusted OR [ORa] = 7.37; 95% CI, 1.99 to 27.32) and diarrhea (ORa = 6.47; 95% CI, 2.00 to 20.91). No significant difference in regurgitation was observed (ORa = 0.49; 95% CI, 0.04 to 5.58). Among SRMA cases, gastrointestinal signs were more likely to be present prior to corticosteroid medication (ORa = 5.76; 95% CI, 2.07 to 15.97).
Gastrointestinal signs (specifically vomiting and diarrhea) were more common in dogs with SRMA compared to controls.
Further research is needed to investigate concurrent gastrointestinal inflammatory disease in dogs with SRMA.
评估与对照群体相比，患有类固醇反应性脑膜炎-动脉炎（SRMA）的犬只是否更频繁出现胃肠道症状。我们假设患有SRMA的犬只出现胃肠道症状的几率高于对照组。
在一项单中心回顾性病例对照研究中，通过爱丁堡大学皇家（迪克）兽医学院小动物医院的机构数据库医疗记录，确定2018年12月至2023年12月期间被诊断为SRMA的犬只。收集的数据包括特征、脑脊液分析结果、血清C反应蛋白水平、呈现的临床症状以及皮质类固醇治疗初始阶段之前和期间胃肠道症状的存在情况。对照组由同期住院且住院时间相似、未因胃肠道症状转诊且有完整医疗记录的年龄匹配犬只组成。
每组纳入50只犬。SRMA组更频繁报告胃肠道症状，呕吐几率显著增加（调整后比值比[ORa]=7.37；95%置信区间，1.99至27.32）和腹泻（ORa=6.47；95%置信区间，2.00至20.91）。反流未观察到显著差异（ORa=0.49；95%置信区间，0.04至5.58）。在SRMA病例中，胃肠道症状在皮质类固醇用药前更可能出现（ORa=5.76；95%置信区间，2.07至15.97）。
与对照组相比，患有SRMA的犬只胃肠道症状（特别是呕吐和腹泻）更常见。
需要进一步研究调查患有SRMA的犬只并发胃肠道炎症性疾病的情况。
